Cerevance’s attempt to unlock the first-line Parkinson's disease market has hit a snag, with solengepras performing no better ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in solengepras patients compared to placebo ...

Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based ...

UK-based clinical-stage biopharmaceutical company Cerevance has announced top-line results from the Phase II ASCEND trial of solengepras as an investigational monotherapy in patients with early, ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

Merck & Co's earlier efforts to find new therapies for Alzheimer's disease resulted in failure, but the company is returning to the field via an R&D alliance with UK biotech Cerevance that will ...

Solengepras showed evidence of potential benefit in functional and non-motor symptoms versus placebo as measured by MDS-UPRDS Parts I, II, NMSS, and ESS, consistent with its novel non-dopaminergic ...